Neurocrine Biosciences (NBIX) Tax Provisions (2019 - 2026)

Neurocrine Biosciences has reported Tax Provisions for 8 years, with the latest figure at $48.9 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions rose 619.12% year-over-year to $48.9 million; the trailing twelve-month figure through Mar 2026 stood at $268.9 million (up 67.64% YoY), and the FY2025 full-year result was $226.8 million, up 56.74% from the prior year.
• Tax Provisions for Q1 2026 stood at $48.9 million, down from $85.7 million in the prior quarter.
• The five-year high for Tax Provisions was $85.7 million in Q4 2025, with the low at -$26.7 million in Q1 2023.
• Historically, Tax Provisions has averaged $33.1 million across 5 years, with a median of $32.5 million in 2023.
• Annual changes were most pronounced in 2023 — Tax Provisions slumped 456.0% — and 2026, when it jumped 619.12%.
• Neurocrine Biosciences' Tax Provisions stood at $28.9 million in 2022, then soared by 74.74% to $50.5 million in 2023, then grew by 17.82% to $59.5 million in 2024, then jumped by 44.03% to $85.7 million in 2025, then plunged by 42.94% to $48.9 million in 2026.
• The last three Tax Provisions figures came in at $48.9 million (Q1 2026), $85.7 million (Q4 2025), and $82.3 million (Q3 2025), per Business Quant data.